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Abstract

Acute lymphoblastic leukemia (ALL) is the most common form of cancer among
children and can be lethal to the adult population. Though 80% of patients with ALL
reach complete remission after treatment, about 20% of those diagnosed fail to remain
cancer-free. Genetic rearrangements are the hallmark of relapsed ALL, but the
mechanism by which these rearrangements occur is still unclear. Recent research
suggests these mutations may be detectable during initial diagnosis. If researchers are
able to accurately assess the probability of relapse during diagnosis by analyzing the
genome of the leukemic cells, the likelihood of administering effective therapy would
increase. Providing patients with a more appropriate therapy early on may prevent relapse
altogether or increase survival rates after treatment for relapsed ALL patients.
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Genetic Relationships and Therapeutic Options for Relapsed Acute Lymphoblastic
Leukemia
Introduction
In 2016, there were 6,590 new cases of ALL including about 1,400 deaths
(Terwilliger & Abdul-Hay, 2017). The distribution of ALL cases in the US is bimodal, in
that the disease peaks in children and again in adults around the age of 50. Adults are
more likely to experience complications, evidenced by only 30–40% achieving full
recovery and remission. Remission is broken down into partial and complete remission
groups, with the latter defined as no evidence of the disease, although cancer may still be
present in the body. Partial remission is the state at which leukemic blasts have
disappeared, though there may be evidence to support that they are still circulating.
Increasing age correlates with decreased survival rates, which is especially poor for
patients over the age of 60 due to unfavorable biology, comorbidities, and an inability to
tolerate intensive chemotherapy (Terwilliger & Abdul-Hay, 2017).
ALL specifically involves diseased lymphocytes, a group of white blood cells
consisting of B cells and T cells which produce antibodies and attack foreign pathogens,
respectively. Precursor B-ALL is highly prevalent among children and the adult
population, making up about 75% of ALL cases, whereas T-ALL is less common making
up the other 25% (Raetz & Teachey, 2016). Within these large classifications, there are
many different subtypes of ALL that are grouped according to similarities in genetic
alterations and rearrangements of DNA sequence. Subtypes of B cell ALL are broken
down into a hyperdiploid and hypodiploid subtype, depending upon the number of
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chromosomes present. Hypodiploidy ALL is characterized by cancer cells containing 2431 chromosomes. These types of ALL have poor outcomes due to the effects on tyrosine
kinase and RAS signaling, which is seen in 71% of cases. Low-hypodiploidy ALL is
characterized as containing 29-32 chromosomes, and the majority of these cases affect
gene expression in the following pathways: p53, IKZF2, and RB1 (Terwilliger & AbdulHay, 2017). Also, there are six different identified subtypes depending upon the location
of translocation. Two of the most prevalent subtypes within this group are translocation
within the Philadelphia chromosome, which creates the BCR-ABL1 fusion gene, and
translocations involving tyrosine kinases or cytokine receptors, which are known as
BCR-ABL1-like ALL. The specific translocations and their downstream effectors are
strong targets for therapy as they regulate cell proliferation (Terwilliger & Abdul-Hay,
2017).
Due to the genetic mutation existing in different locations of chromosomes and
involving different proteins, the progression of the disease and response to treatment are
variable among the subtypes. This identifies a need to further investigate the nature of the
disease for each subtype, and the importance of developing drugs that effectively treat the
specific disease. Chemotherapy has been widely used as an effective treatment option
consisting of vincristine, corticosteroids, and the addition of anthracycline with
allogeneic human stem cell transplantation (HSCT) when eligible candidates and donor
standards are met (Kato & Manabe, 2018). HSCT has been found to be very effective
against rare and resistant forms of cancer, but it does not provide a cure as patients still
relapse after this treatment (Ceppi et al., 2016). However, researchers are still devoting
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time and effort to further explore possible targets for treatment due to patients
experiencing relapse of the disease after partial or complete remission (Ceppi et al.,
2016). Scholars are attempting to target signaling pathways that are compromised by
genetic alterations which induce the proliferation of leukemic cells in the bone marrow,
blood, and extramedullary sites (Terwilliger & Abdul-Hay, 2017). Intramedullary relapse
is the most common relapse site for ALL, and prognosis has a variety of ranges for these
patients (Zhang et al., 2018).
Relapse, Drug Resistance, and Genetic Relationships
Though 80% of patients with ALL reach complete remission after
chemotherapy/radiation treatment regimen, 20% of the pediatric population still
experiences relapse of the disease. There are two conventional mechanisms by which
relapse occurs: relapse may be due to a cellular clone that is resistant prior to treatment,
or resistance may be induced by treatment. (Choi et al., 2007). When studying relapsed
cells, researchers aim to identify the specific pathways by which they resist treatment to
better prevent disease progression. Relapsed leukemic cells are found to be more related
to the original leukemia rather than the secondary, or relapsed, leukemia (Bhatla et al.,
2014). There are many different mutations and contributors to relapse of ALL, and many
subgroups have been identified. (Bhatla et al., 2014). Research suggests the patients’
bodies may also have a pre-disposition to the metabolism of drugs. Each body has a
unique way by which it attempts to evade therapy and resist treatment. Relapse-specific
pathways should be targeted in order to reverse the resistant nature of these cells (Tasian
et al., 2015).
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In a study conducted in Sydney, Australia, polymerase chain reaction (PCR) was
used to detect antigen receptor gene rearrangements in immunoglobulins and T-cell
receptors. In relapsed patients, PCR identified new rearrangements called relapse clones.
Cohort A consisted of patients who had relapsed though minimal residual disease (MRD)
results were negative while Cohort B was selected due to availability. Twenty-seven
patients were analyzed, 23 with pre-B ALL and four with T-ALL. The time to first
relapse ranged between 5-59 months and 12 patients relapsed while still receiving
therapy. In all cases, prediction of relapse failed, and the original target was replaced by a
new clonal rearrangement (Choi et al., 2007). Overall, 80% of the patients experienced an
altered clonal rearrangement and 21 of the patients had one conserved marker before and
after treatment. A more specific and quantifiable method, real-time quantitative PCR,
RQ-PCR, was then used on eight leukemic cell samples to find that the relapse clonal
marker was present at low levels upon diagnosis but was undetected. Induction
chemotherapy caused the major clonal sample to decrease by 1000-fold, but the minor, or
relapse clone, was reduced by 30-40-fold, suggesting that it was not only present at
diagnosis, but was not reduced by therapy causing MRD. This research suggests therapyacquired resistance is not a mechanism by which relapse occurs. Instead a subclone
present at diagnosis is indicative of relapse (Choi et al., 2007).
Interestingly, quantity of the relapse clone present at diagnosis was also directly
correlated to time to first relapse. For example, in four samples where the relapse clone
was unable to be detected, the patients had longer remission times compared to the
patients where relapse clones were detected. One patient had a subclone detected, but the
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levels were too low to quantify using RQ-PCR, and this patient had the longest remission
time. These findings can be used to target therapy to reduce these subclones present at
low levels at diagnosis and to decrease overall relapse rates (Choi et al., 2007).
Apoptosis inhibition is a hallmark of cancer and leukemia relapse. CXCL10 is a
gene that is responsible for encoding a protein, CXCL10, involved in inflammatory
response and has also been found to protect the cell from apoptosis in patients with ALL.
Researchers studied this mechanism using cytarabine, which normally causes NALM-6
cells, a precursor to B-cells, to die by downregulating Bcl-2, a death inhibitory protein
(Gomez et al., 2015). When the sample was treated with cytarabine in the cerebral spinal
fluid, CSF, relapse sample, CXCL10 protected the cell from the down regulation of Bcl-2,
and inhibited apoptosis of NALM-6 cells. To further identify the protective nature of this
chemokine, the researchers analyzed caspase activity. Normally, cytarabine activates
caspases 3, 8, and 9 to induce apoptosis. However, CXCL10 inhibited caspase activity to
the state at which cleaved caspase 8 was almost undetectable in the sample (Gomez et al.,
2015). Therefore, CXCL10 may serve as a favorable target for drugs. If agents are able to
decrease the expression of CXCL10, leukemic cells will have a higher chance of
undergoing apoptosis when treated by cytarabine.
Another prominent gene, BIRC5, is upregulated in many ALL relapse patients.
The protein product normally initiates apoptosis, but when BIRC5 is upregulated as seen
in leukemic blasts, it inhibits the activation of caspases and apoptosis, allowing continued
proliferation of leukemic cells. These protein products are considered an attractive target
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for treatment as researchers aim to identify agents that reverse the signature of the
relapsed cancer by restoring sensitivity to the drug (Bhatla et al., 2014).
Drug resistance is the underlying property of leukemic blasts that leads to relapse
of the disease and resistance can cause lower remission rates of leukemic cells or cause
MRD (Pierro et al., 2017). MRD refers to a disease state in which cancer cells remain in
the body after completion of treatment but are no longer detectable by current
technologies. MRD has been used as the dominant predictive marker of chemoresistance
and relapse. However, this disease state has failed to predict accurate outcomes in cases
with unclear etiology (Choi et al., 2007) Patients who are MRD-positive only have a 25%
chance of achieving 5-year remission (Gokbuget et al., 2017). HSCT improves this
statistic to 44%, but only half of these patients are eligible for this treatment option due to
rapid progression of relapse (Gokbuget et al., 2017).
Some scholars suggest relapse due to drug resistance may be caused by the tumor
microenvironment. Tumor cells secrete and respond to chemokines, which guide
leukocyte migration throughout the body and can alter anti-apoptotic pathways. This
phenomenon has been observed in the central nervous system, CNS, with the survival of
ALL tumor cells in organs of the CNS (Gomez et al., 2015). Out of 72 patients with BALL and 12 patients with T-ALL, there was an increase in chemokine receptors in the
bone marrow and CSF when compared to normal tissues. In the CSF, expression of the
chemokine receptor CXCL10 was increased. In addition, the CXCL10-CXCR3 complex
recruited ALL cells to locations harboring lower concentrations of the antileukemic
drugs, cytarabine or methotrexate, thus decreasing the efficacy of treatment. It seems that
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if ALL cells express chemokines made in the blood brain barrier, BBB, due to migration,
the ALL cells will compete with antileukemic drugs for their survival. Therefore, the
cancer cells seem to become resistant to treatment, MRD persists, and the patient relapses
(Gomez et al., 2015). Recurrent relapse of the CNS may occur due to the lack of
penetration by the drug imatinib. A solution to this problem was a drug called dasatinib,
which is an ABL kinase inhibitor. Dasatinib is effective by binding to these kinases and
blocking their growth-promoting activities. This drug is effective due to its ability to
penetrate the BBB, which was observed in a mouse model of pediatric Philadelphia (+)
ALL. It has been previously documented that the most common cause of relapse was due
to a mutation of the ABL kinase domain (Terwilliger & Abdul-Hay, 2017).
Many mutations and genetic correlations are associated with ALL. Genes
involved in B cell development, CDKN2A/B, PAX5, IK2F1, and EBF1 were all found in
this mutated form in the relapsed population. There has also been relapse associated with
MSH6, a gene coding for a protein involved in DNA mismatch repair, in attempt to
resolve unwanted mutations (Bhatla et al., 2014). Other deletions are found in the
glucocorticoid signaling pathway in many relapsed patients. A study conducted found
that 10-14% of the relapsed population had deletions in genes BTG1 and TABLIX, which
are genes for a coactivator of the glucocorticoid receptor and function to degrade
inhibitors of the nuclear corepressor complex (NCoR), respectively. Alterations of the
NCoR are prevalent in relapsed blasts, or immature cells, and can lead to steroid
resistance. Understanding this altered pathway can better identify pharmaceuticals that
can be effectively metabolized by the body (Bhatla et al., 2014).
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To be considered relapse-associated mutations, the mutations must either be
retained from diagnosis and persist to relapse, or they must arise after treatment and
correlate to relapse of the disease. Regardless of total sample size, the mutation must be
present in at least two patients and absent in all patients of the non-relapse group in the
individual study. A prominent biomarker in the study of relapsed ALL and progression of
the disease is the transcriptional coactivator and acetyl transferase CREBBP. Mutations of
this gene comprise 20% of all relapsed cases. (Iacobucci & Mullighan, 2017). CREBBP is
responsible for coding the CREB binding protein, which functions to control cell division
and maturation. Mutations in the functional domain of CREBBP suggest that it alters the
function of the gene product and its function. Research also suggests that these mutations
impair the regulation of glucocorticoid signaling, which will influence the cells’ response
to therapy (Mullighan et al., 2011).
Other prominent epigenetic regulators involved in the pathogenesis of leukemia
with patients with Philadelphia negative pre-B-ALL, or Ph (-) pre-B-ALL, are SETD2,
and the transcription factors NR3C1 and PAX5. SETD2 has been previously seen to have
tumor suppressor activity in breast cancer and renal cell carcinoma. Mutations here
appear to form after chemotherapy and are unique to relapse. NR3C1 codes for a
transcription factor and glucocorticoid receptor. This gene activates expression to
glucocorticoid response. Loss-of-function mutations in this gene are associated with
chemotherapy resistance (Xiao et al., 2016). The protein PAX5, a B cell transcription
factor, was studied and observed during B cell development in patients with BCP-ALL.
PAX5 was overexpressed in all developmental stages when compared to that of healthy B
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cell development (Good et al., 2018). Other relapse-associated genes, such as KRAS and
PTPN21 are found in a lower frequency of patients (Xiao et al., 2016). Mutations of these
genes were found to be in the major functional domains which altered protein function.
KRAS is an oncogene in the RAS-MAPK signaling pathway and these mutations suggest
promoting tumorigenesis (Xiao et al., 2016). PTPN21 codes for a protein tyrosine
phosphatase involved in the PI3K-AKT, MAPK, and JAK-STAT pathways, all involved
in regulating cell growth and proliferation (Xiao et al., 2016). Identification of the
mutated genes that impair protein function can help to guide drug targeting. If mutations
inhibit the normal function of these pathways, drugs may be able to target these proteins
and restore their function to regulate cell growth.
Independent studies of three separate patients with Ph-negative pre-B-ALL found
three separate and distinct patterns. In patient 1, the primary and relapsed tumors had
eight consistent mutations found in seven genes. This pattern seems to suggest the
mutations were present at diagnosis and persisted through therapy to cause relapse. In
patient 2, there seemed to be a divergence in mutations from the original to the relapsed
tumor (Xiao et al., 2016). The tumors shared two single nucleotide variations, SNVs,
CREBBP, and RGS11 mutations, but there were five additional mutations found at
diagnosis that were not present at relapse. Also, there were two relapse-specific mutations
in USP54 and NCOR2. In patient 3, there were no mutations shared between relapse and
diagnosis. Four distinct mutations were found at both stages and were unique from each
other. This data suggests unique mutations to relapse which can serve as therapeutic
targets, especially to prevent use of ineffective treatment (Xiao et al., 2016).
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B cell Development.
B cells either originate in the bone marrow or peripheral blood. These cells are
immature B cells in that when rearrangements cause proliferation to the tumor states,
their development into normal cells is halted and they are unable to develop into mature
B lymphocytes (Good et al., 2018). When genetic lesions are present and make DNA
copy number changes, the proliferation of leukemia can be initiated (Iacobucci &
Mullighan, 2017). Other research has aimed to study the development of B cells in the
following stages: pre-pro-B cell, pro-B cell, and pre-B cell stages. 60 bone marrow
aspirations of patients with B cell precursor ALL, or BCP-ALL, were obtained as well as
samples from five non-diseased bone marrow donors. Principal component analysis
(PCA) was used to compare the leukemic cells to six cellular features in normal B celldevelopment. PCA organizes observations of correlated variables into linear components
that are not correlated (Good et al., 2018). These features were distinct as they were
separated by expression of certain proteins that revealed maturity of the cell through
development. The cells were assigned to the population of “best fit” as the leukemic cell
does not completely resemble a normal developing B cell. They found that at all cases of
study, expansion of the cells was observed in more than one stage of development. With
a sample size of 54, 31% of the sample relapsed, which was higher than the literature
values of 15-20%. There were three distinct patterns that were observed after PCA: an
expression pattern with slight differences to the normal development, overexpression at
all stages of development, or a developmentally abnormal expression pattern (Good et al.,
2018). Though the proteins that were expressed in the BCP-ALL group resembled that of
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a healthy B cell, the degree to which they were expressed was different. For example,
PAX5 was found to be overexpressed in all developmental stages in the BCP-ALL group.
Other signaling pathways such as mTOR and CREB were also elevated in this group
when compared to the control sample. Therefore, overexpression of the same proteins
found in healthy B cell development was correlated to overexpansion of cells and
progression of the disease. This provides much insight for researchers to develop ways to
restore regulation and feedback inhibition within the pathways to maintain normal
development. (Good et al., 2018).
Treatment Options.
After the initial induction chemotherapy, treatment can be further administered if
the disease state persists. Common types of chemotherapy include alkylating agents,
antimetabolites, topoisomerase inhibitors, anti-tumor antibiotics, mitotic inhibitors, and
corticosteroids. Alkylating agents target the cell cycle and damage DNA, which halts it
replication and inhibits mitosis. Antimetabolites insert into DNA and RNA by acting as
building blocks of the genetic code. This interference also inhibits DNA replication and
cellular reproduction. Topoisomerase inhibitors impair the function of topoisomerases,
which function to uncoil DNA in preparation for replication. If DNA is not unwound, it
will not be replicated, and the cell cycle is unable to continue to completion. The most
common type of anti-tumor drugs is a type anthracycline, which impair the function of
other enzymes involved in replication. Mitotic inhibitors are a wide range of drugs that
halt division in various stages of mitosis and inhibit enzymes from making the necessary
proteins required to perform mitosis. Lastly, corticosteroids are hormone-like drugs that
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prevent nausea and allergic reactions that are side effects of the above chemotherapy
agents. Though chemotherapy is a widely used treatment for ALL, side effects exist due
to the inability of the drugs to differentiate the cancer cells from the healthy cells.
Therefore, there is damage to healthy tissue when treating the disease. Vincristine sulfate
liposomes injection (VSLI) is a treatment option created to solve the problem of toxicity,
while still maintaining efficacy. For those who have poorer responses to chemotherapy,
especially adults with ALL, HSCT has been shown to successfully help patients achieve
complete remission and long-term survival of the disease (Terwilliger & Abdul-Hay,
2017).
However, a percentage of patients still experience relapse of ALL after
chemotherapy, radiation, and HSCT. For adults with ALL, relapse after treatment is the
most common cause of death due to patient survival being only 10%. (Xiao et al., 2016).
Therefore, it is necessary to develop new forms of therapy to help treat these adult
patients with poor outcomes. Researchers have attempted to find mutations associated
with relapse after HSCT, specifically in patients with Ph (-) B cell ALL, a cancer that has
been unexplored in the past. In this study, sequencing took place at diagnosis, after
complete remission, and at relapse, to compare genetic differences. There were found to
be 102 sequence alterations and 25 distinct mutations in 23 genes that contributed to
relapse. Many genes that had not been observed to be mutated in leukemia previously
were found to be mutated in this cohort (Xiao et al., 2016). Fifty-eight Ph (-) B-ALL
adult patients with normal karyotypes were studied, which had received HSCT from
2004-2008. In 2014, 28 of the patients had relapsed, with time to first relapse ranging
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from 2-33 months. 30 patients did not experience relapse after being followed for 50.75
months. Of the patients that relapsed, 13 had somatic mutations of non-cancerous cells of
the bone marrow, while only five had somatic mutations in the non-relapse group.
Therefore, the genetic code of somatic cells must also be considered when identifying
cancer mutants to discover which mutations are unique to cancer (Xiao et al., 2016).
Other Forms of Treatment.
A histone deacetylase inhibitor, vorinostat, is a probable agent that can reverse the
epigenetic signature of relapse by maintaining the accessibility of chromatin to
transcription factors. This agent has also been found to synergize with chemotherapy
after relapse in clinical trials (Bhatla et al., 2014).
Decitabine is a demethylating agent, which was also successful in flipping the
signature of relapse at diagnosis (Bhatla et al., 2014). In this study, researchers used this
information to guide treatment options to counteract the behavior of relapsed cells. When
treated with BEZ235, a PI3K/mTOR inhibitor, the overall abundance of active p4EBPI
was reduced in pro-BII cells, but pS6 was still observed abnormal levels (Good et al.,
2018). These proteins are important in the initiation of translation for protein synthesis
and overall cellular growth and metabolism (Qin et al., 2016). This suggests that there
are multiple ways to phosphorylate S6 and alternative signaling pathways that must be
taken into consideration when designing treatment plans.
A new drug that has been studied in an attempt to improve efficacy and reduce
toxicity of disease is clofarabine, which is a deoxyadenosine analog. The mechanism by
which this drug improves outcome for relapsed ALL is by inhibiting ribonucleotide
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reductase and DNA polymerase. Apoptosis is then initiated by the release of cytochrome
c from the mitochondria. A previous phase I clinical trial of this drug was performed at
the University of Texas M.D. Anderson Cancer Center with 25 patients, assessing drug
efficacy by analyzing complete and partial remission. Complete remission was defined by
no evidence of leukemic blasts, while partial remission was characterized by
disappearance of the blasts. This means that in partial remission, though there may not be
obvious blasts present, there may be evidence of their presence based on protein
expression. In this study, five patients achieved complete remission and three achieved
partial remission. In addition, the drug seemed to lack neurotoxicity. In a follow-up phase
II clinical trial, 61 patients who had relapsed ALL were given clofarabine treatment of 52
mg/m2 drug given intravenously for 2 hours daily and a total of five days (Jeha et al.,
2006). This treatment was repeated every two-six weeks. 12 patients achieved complete
remission accounting for 20% of the population size, and five of these patients did not
have successful platelet recovery. Six patients achieved partial remission accounting for
10% of the population size. Nine of the patients were able to proceed to HSCT where
seven achieved either complete or partial remission status. Thirty-five of the patients in
the population were experiencing a refractory state following their most recent treatment.
It is pertinent to report that 25% of the population died through the duration of this study
(Jeha et al., 2006). Eight deaths were due to disease progression, two deaths were
possibly drug-related, and three deaths were multifactorial, and the etiology was unclear.
Infection was common among this study, many instances of which were systemic
infections or sepsis due to cytokine storms. Overall, clofarabine appeared to be an
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effective drug, as one third of the population achieved at least partial remission status.
Also, 50% of the 12 patients that received complete remission had not responded to prior
treatment. This drug shows promise in advancing ALL therapy, as it allows patients to
reach an eligible state to proceed to HSCT and it proves to be active in patients with
relapsed ALL. Further studies should continue to analyze clofarabine to improve its
efficacy and analyze patients that are most suitable and respond appropriately to this drug
(Jeha et al., 2006).
Another drug that is currently being studied is blinatumomab, a bispecific T-cell
engager antibody, specific for CD19 and CD3. This drug is believed to activate T-cells
which directly causes a B cell inflammatory response and ALL cell lysis. Blinatumomab
was first seen to be effective in a study where 80% of the patients became MRD-negative
and 60% of the patients achieved complete remission after 33 months (Terwilliger &
Abdul-Hay, 2017).
In a prior phase 3 study, it showed to be an effective treatment in patients with B
cell ALL and persistent MRD after chemotherapy. In the first two phases of the study,
this drug achieved 43-69% MRD response, which improved by the third phase of the
study. In the phase 2 study, 20 patients received Blinatumomab in four to seven-week
cycles, at a dosage of 15 μg/m2/day intravenously. 80% of the experimental population
had MRD responses after treatment (Gokbuget et al., 2017). At the first follow-up at 33
months, 60% of the patients were still in remission following treatment. At the final
follow up after five years, ten of the patients had continued to complete remission status.
After the first cycle of Blinatumomab, nine patients were eligible and proceeded to HSCT
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treatment. The ten patients who were cancer-free after the five-year follow-up included
five patients who received HSCT and five patients who did not proceed with this
treatment. Therefore, the drug proved to have efficacy with or without this treatment plan
supplementation (Gokbuget et al., 2017). Of the six patients who had Ph-negative BALL, four of the patients were in complete remission after five years and none of these
patients progressed to HSCT. Since half of the patients had long-term remission have
treatment with blinatumomab, this drug is a possible therapeutic option for MRD-positive
patients. Further studies are needed to warrant early administration of this drug rather
than upon relapse and to further improve the long-term survival rates of relapsed patients
(Gokbuget et al., 2017). Blinatumomab may have the ability to serve as induction therapy
and therefore decrease the overall incidence of ALL relapse.
Another drug, ponatinib, is a tyrosine kinase inhibitor which resists such
mutations in the BCR-ABL1 kinase domain. While research is ongoing, this drug has
been approved for treatment for resistant Ph-positive ALL (Terwilliger & Abdul-Hay,
2017).
A drug that is used to treat the less common ALL of precursor T-cell lineage is
called nelarabine. This drug is a T-cell specific purine nucleoside analog and has been
FDA-approved. The mechanism by which nelarabine targets cancer is by accumulation of
T-cells and subsequent inhibition of DNA synthesis, which ultimately causes apoptosis of
the cell. A trial with this drug achieved a 31% complete remission rate for patients with
T-cell ALL (Terwilliger & Abdul-Hay, 2017).
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Recent research has aimed to determine if patterns of survival after relapse have
changed with the development of more intensive therapies and contemporary medicine.
In a study that followed a total of 9,585 patients in clinical trials from the years 19882002, 20.5% of these patients experienced relapse of the disease. In prior research, time
to first relapse served as the strongest indicator of survival as an endpoint after treatment
(Nguyen et al., 2008). For those patients relapsing in less than 18 months after first
remission, a five-year survival rate is estimated at 21.0+/- 1.8%. Current treatment is
suboptimal at achieving long-term survival or even short-term remission. Prior literature
shows that early bone marrow relapse predicts 0-15% five-year survival rates,
intermediate medullary relapse predicts a 10-40% chance of survival, and late bone
marrow relapse patients have a 14-50% chance of survival (Nguyen et al., 2008). Other
sites of relapse include the CNS with a 51% chance of survival and the testes with a
rising 53-84% survival rate. Of the 1,961 patients who relapsed, 57.3% were bone
marrow, 13.5% concurrent marrow, 20.9% CNS, 5.3% testicular, and 3.1% other
extramedullary. Researchers found that the highest prevalence of relapse fell in children
who were less than one year old, or older than ten. Also, males had a higher percent
relapsed than females. 20% of the population who relapsed had an initial white blood
count, WBC, of greater than 100,000 per μL. Ethnicity also played a role as more African
American and Hispanic patients experienced relapse when compared to those of
Caucasian ethnicity (Nguyen et al., 2008).
Since bone marrow relapse was the site of the majority of cases, bone marrow
morphology was investigated and given a status rating depending on the percentage of
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leukemic blasts existing within the marrow. M1 marrow was defined by less than 5% of
circulating blasts, M2 ranged from 2-25%, and M3 was characterized by greater than
25%. Out of the 4,064 patients with M1 marrow, 16.2% relapsed at day 7 and 21.2%
relapsed at day 14. There were 630 patients with M2 or M3 marrow at day 14, and 41.7%
of these patients relapsed. Therefore, a slow early response to therapy is associated with
event-free survival. Interestingly, patients who relapsed earlier had a lower chance of
long-term survival independent of time of treatment. This suggests that although
intensive treatment has been advancing with modern medicine, there was no evidence of
increasing survival rates for early relapse patients (Nguyen et al., 2008). High risk
patients also demonstrated an increased mortality rate independent of time. Overall,
patients who were male, less than 1 year old or 10 or older, of T-cell lineage, or
experiencing CNS relapse, had a higher chance of relapse throughout the time of the
study. There has been improved event-free survival for patients who receive intense
treatment upon initial diagnosis, however it is still unclear how to improve this for
patients who fail initial treatment. This study reinforced the fact that time of relapse is a
strong indicator of overall survival and it also points to the site of relapse as another
prominent predictor (Nguyen et al., 2008). The challenge is to find appropriate patients at
diagnosis who would benefit the most from initial, intense therapy. Further studies should
be conducted to develop agents that may not normally be used in initial chemotherapy
that could improve survival rates after relapse for patients with ALL (Nguyen et al.,
2008).
CD19 Antigen Relapse.
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Though not frequent, CD19 negative relapse is found in some patients after
chemotherapy and CD19-targeted T-cell immunotherapies. The mechanism of such
relapse is not well understood and explains the poor rates of survival. Though CD19 is
the primary antigen expressed on B cells, it has few cell surface markers amenable to
flow cytometry in the relapsed state. Therefore, loss of this antigen causes relapse of
CD19 ALL to go undetected. Researchers have attempted to study B cell lineage antigens
CD20, CD22, CD24, intracellular CD79a ([i]CD79a), as well as CD10, which is the most
common antigen among ALL patients (Mejstrikova et al., 2017).
Blinatumomab is a new drug which has gone through many phases of study in
clinical trials, specifically in the context of CD19 relapse. In past trials, 39% of the 70
pediatric patients studied achieved complete remission and 14 patients had complete
MRD response to this therapy. However, 71% relapsed within 6 months and had very
poor prognoses. In a study from 2017, five patients were analyzed in two separate phases
which had all experienced CD19 negative relapse. The first patient achieved complete
remission during cycle one and complete MRD response. But during cycle three, about
three months after remission, the patient experienced relapse of the disease (Mejstrikova
et al., 2017). The second patient also achieved remission in cycle one and complete MRD
response. However, two weeks after induction of blinatumomab treatment, the patient
experienced CD19 positive relapse. The patient continued blinatumomab and achieved a
second remission in cycle two. The patient persisted to relapse two weeks after the
second round of treatment but was CD19 negative. This patient died due to progression
of the disease before the study was over. The third patient died as well due to relapse
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about three months after induction of treatment (Mejstrikova et al., 2017). Prior to this,
the patient had complete remission in cycle one, but flow cytometry showed the presence
of CD19 negative blasts. Patient four experienced CD19 negative relapse in cycle four,
about 45 months after remission. The fifth patient had CD19 positive blasts upon
induction of therapy which changed to CD19 negative in cycle one, displaying the gain of
monocytic phenotype. This data also emphasizes the importance of alternative antigens to
detect this relapse due to the problem of accurate representation of disease progression
when CD19 is absent as a cell surface marker. CD22 positive blasts were found to be
associated with CD19 negative relapse, which may serve as an effective marker. It is
important to continue monitoring patients after CD19 negative relapse in order to develop
directed therapies to treat this specific type of disease progression (Mejstrikova et al.,
2017).
Philadelphia (+) ALL.
Philadelphia (+) ALL has had a history of poor outcomes in regard to relapse.
This leukemia is characterized by a gene expression similar to BCR-ABL Ph (+),
however, it lacks the oncogene for BCR-ABLl. In this study, 46 patients with pre-B-ALL
relapsed after treatment, 72% of these patients being only at medium risk according to
MRD. This indicates the MRD quantitative factor may be accurate in predicting relapse
in patients with Ph-like ALL. Standard and medium risk participants were treated with
BFM four drug chemotherapy which consists of daunorubicin, vincristine, PEG
asparaginase, and methotrexate, along with prednisolone and intrathecal methotrexate.
High risk patients were given three more intense cycles of chemotherapy and stem cell
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transplant therapy in addition to the above treatment. After RQ-PCR and Sanger
sequencing, they found that the majority of participants had rearrangements in the gene
CRLF2 and mutations in the JAK2 gene (Iacobucci & Mullighan, 2017).
CRLF2 codes for cytokine receptor-like factor 2, or thymic stromal derived
lymphopoietin receptor. Translocation of this gene into the heavy chain of the
immunoglobulin can down-regulate CRLF2, which directly affects the signaling
pathways of JAK-STAT and Ras. Modern advancements in therapies have helped
children with ALL to have better outcomes, including targeting the JAK-STAT,
PI3K/mTOR, and Bcl-2 signaling pathways. Tyrosine kinase inhibitors have also shown
to have success in treating Ph-like ALL (Iacobucci & Mullighan, 2017). If these therapies
are successful, the cancer will no longer exist in an environment that equips the cells with
the proteins needed to grow. Thus, the cells will die, and the tumor shrinks. Targeted
therapies also impair the ability of the cancerous cells to undergo cell signaling with other
parts of the body, inhibiting metastasis. CRLF2 has been previously related to poor
outcome due to overexpression of the gene and the downstream proteins. Of this
majority, 77.7% of the participants relapsed, suggesting a clear indication that CRLF2
rearrangements are strongly correlated to relapse risk. Knowing this information can
help clinicians better treat patients that are at risk for this gene rearrangement to prevent
future relapse. After these patients were followed for five years, 78% survived due to this
therapy, or further stem cell transplant intervention (Heatley et al., 2017). Philadelphialike ALL is also characterized by deletions in IK2F1 which causes deregulation of
cytokine receptors and tyrosine kinase signaling (Iacobucci & Mullighan, 2017).
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Indications of Relapse and Race.
The Mexican race has been known to have higher mortality rates and incidences
of relapse than any other race, as well as the highest number of patients with ALL
compared to population size, than other developed countries. Mexico has not seen
improvements in outcome or survival rates though chemotherapy regimens have
advanced. The aim of this study was to determine factors associated with relapse in this
race by using transcriptome analysis. In a study of 54 patients with ALL, bone marrow
samples were obtained, and the patients were followed from 2014-2017 (Nunez-Enriquez
et al., 2016). Eleven patients relapsed before the first 18 months and half were considered
high risk at diagnosis. Interestingly, less than 20% of these patients had common genetic
rearrangements secondary to ALL. Only one third of ALL patients from developed
countries are considered high risk and about 32% of these individuals exhibit the
common gene rearrangements in their genome. Over half of the population that relapsed
were considered standard risk, and many of these individuals relapsed during treatment
(Nunez-Enriquez et al., 2016).
Very early relapse was found to be common within this population, and time of
first relapse has been known to be a significant indicator of survival as an endpoint. The
11 patients that relapsed achieved this stage in an average of 10.6 months and five of
these patients died after isolated bone marrow relapse. It has been previously understood
that time to first relapse and relapse site are large predictors of survival, and this is
especially evident in the Mexican ALL population (Nunez-Enriquez et al., 2016).

[SHORTENED TITLE]

26

Many genes were found to be up- and down-regulated which play roles in B and
T cell activation, EGF and FGF signaling, and induction of apoptosis pathways. The
highest abnormally expressed gene was BLVRB and previous data suggests that this gene
is associated with prednisolone therapy resistance, a hallmark of relapse. TMODI was
another gene shown to be overexpressed in this cohort. This gene codes for an
erythrocyte membrane protein and when it is mutated, red blood cells’ membranes are
altered, leading to proliferation of cancer cells (Nunez-Enriquez et al., 2016). The PAX5
pathway was overexpressed, however BLNK, an adapter protein in BCR signaling for
apoptosis was down regulated. Mutations of this gene completely block B cell
development, leading to pre-B cell ALL. A knockout mutation was performed with mice
to confirm these findings and the results concluded that the mutation inhibited B cell
development
EBF1 is also a gene which is dependent on PAX5 and deletions are commonly
found in EBF1 to be associated with leukemogenesis in Down Syndrome patients. PAX5
is also a regulator of FLT3, and its increased expression leads to decreased B cell
lymphopoiesis. Loss of PAX5 leads to altered lymphoid and myeloid development
leading to abnormal expression of myeloperoxidase, or MPO, due to the absence of other
myeloid markers. Usually ALL blasts are negative for MPO, but it has been detected in
this cohort and may serve as a biomarker for MRD (Nunez-Enriquez et al., 2016).
Risk Stratification & Predictive Markers of Relapse
Identifying disease risk factors and prognosis is essential when considering
treatment plans for patients with ALL. When considering prognosis and risk, MRD has
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been very effective in predicting success of induction chemotherapy. This is also a way to
assign patients to high, intermediate, and standard-risk statuses and to group treatment
accordingly (Terwilliger & Abdul-Hay, 2017). As age increases, the risk of ALL relapse
also increases (Iacobucci & Mullighan, 2017). Age and white blood cell count at
diagnosis were previously seen as the main factors affecting long term outcome.
However, with advancement in research and technology, the cytology and genetic factors
of leukemic cells have had a much greater effect on accurately predicting outcomes and
appropriate treatment options. High risk patients such as Ph (+) have been previously
predicted to have a 10% chance of one-year survival. However, with recent research
shifting toward cytogenetic factors, scholars have been able to develop tyrosine kinase
inhibitors that have been very effective in treating ALL. Other high-risk subsets consist
of Ph-like ALL in which patients do not respond well to the first round of chemotherapy
and are likely to relapse due to high MRD (Terwilliger & Abdul-Hay, 2017).
Studying the expression of proteins on the leukemic cells and the progression of
the disease at the cellular level can also provide insight into predictive markers for
relapse. Though theories exist that cancer cells become resistant through the induction of
therapy, it has also been widely accepted that resistance is present at the time of diagnosis
and persists through therapy, leading to relapse (Fuster, 2014). Since such resistant cells
are rare, they must be studied on a single-cell basis in order to analyze the cell signaling
pathways that are associated with relapse at diagnosis. There have been prior riskprediction methods to study the rare resistant cells and the phenotypic differences
between non-relapse cells, as well as biochemistry to define the mechanism by which
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these resistant cells evade treatment. However, current methods are not completely
accurate at successfully identifying relapse (Good et al., 2018). Researchers have aimed
to develop a model that would not only predict outcome of disease but identify cellular
features that are indicative of relapse and can be a better predictor of relapse risk than
current models. The name of this model was Developmentally Dependent Predictor of
Relapse, or DDPR. Using this method, the researchers found that pro-BII cells had an
increase in basal activation of the mTOR pathway and pre-BI cells exhibited a decrease
in response to stimulation in the pre-BCR pathway. This model was successful at
determining relapse-free survival after single cell development classification. DDPR was
able to identify cellular features indicative of risk for relapse, and its guided treatment
options available to such patients. These features were not only found at the time of
relapse, in fact, they were evident at diagnosis and persisted at relapse to an
overexpressed state. Regarding cellular behavior, the strength of signaling in the mTOR
pathway was enhanced at relapse, allowing the proliferation of the tumor (Good et al.,
2018).
There were multiple benefits to this approach of studying the leukemic blasts on a
single-cell basis. The researchers found features and identifiable cellular behaviors that
related to clinical outcome. Also, they discovered insight into the mechanisms by which
the tumor state persisted, compared to that of normal B cell development. The most
prominent stage of development for transition from a benign to malignant state was the
pre-pro-B cell to pre-BI cell state. Overall, this study added to the literature and
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knowledge of risk for relapse and devised a model to accurately predict relapse according
to cellular features (Good et al., 2018).
Conclusion.
Fully understanding the multifactorial hallmarks of ALL is the best way to
effectively treat this cancer. High risk patients include those that are Ph (+), exhibit high
WBC counts at diagnosis, harbor CNS disease, contain high-risk genetic rearrangements,
and are hypodiploid. If these factors are first taken into consideration the disease can be
better treated initially and prevent long-term use of toxic drugs. HSCT shows much
promise for long term survival in qualified patients, especially those who are high-risk.
Modern clinical trials of many new drugs have improved prognosis and survival for
relapsed patients following treatment when compared to that of chemotherapy. Since
each ALL case is unique due to patient demographic, family history, and genetic
alterations, it is very unlikely that a single drug or agent will have the capacity to be
effective in all ALL patients. Current researchers strive to continue to advance treatment
options by exploring new agents and targeted therapy.
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